SynthesisClinical transplantation2021
COVID-19 in hospitalized liver transplant recipients: An early systematic review and meta-analysis.
Synthesis in Clinical transplantation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- COVID-19 in hospitalized liver transplant recipients: An early systematic review and meta-analysis.Clinical transplantation · 2021Pooled it
- Impact of COVID-19 on liver transplant recipients: A nationwide cohort study evaluating hospitalization, transplant rejection, and inpatient mortality.World journal of transplantation · 2024Article
- A review of the clinical characteristics and management of immunosuppressed patients living with HIV or solid organ transplants infected with SARS-CoV-2 omicron variants.Frontiers in public health · 2024Review
- Review
- Does COVID-19 infection significantly affect liver transplantation? Results of liver transplantation in the COVID-19 era at a single, high-volume centre.BMJ open gastroenterology · 2023Article
- COVID-19 in patients with liver disease and liver transplant: clinical implications, prevention, and management.Therapeutic advances in gastroenterology · 2023Review
- COVID-19 infection in liver transplant recipients: Clinical features and outcomes from a Canadian multicentre cohort.Canadian liver journal · 2022Article
- Immune Response to COVID-19 and mRNA Vaccination in Immunocompromised Individuals: A Narrative Review.Infectious diseases and therapy · 2022Review
- Clinical outcomes of coronavirus disease 2019 in liver transplant recipients.World journal of hepatology · 2022Article
- Consequences of the first and second COVID-19 wave on kidney transplant recipients at a large Indian transplant centre.Nephrology (Carlton, Vic.) · 2022Article
- SARS-CoV-2 infection in liver transplant recipients: A complex relationship.World journal of gastroenterology · 2021Article
- Impact of COVID-19 on liver disease: From the experimental to the clinic perspective.World journal of virology · 2021Review
- T cell-mediated response to SARS-CoV-2 in liver transplant recipients with prior COVID-19.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2021Article
- Liver injury, SARS-COV-2 infection and COVID-19: What physicians should really know?GastroHep · 2021Review
- Outcomes of Liver Transplant Recipients Hospitalized With COVID-19: A Nationwide Analysis From the United States.Journal of clinical and experimental hepatologyArticle
- COVID-19 in Liver Transplant Recipients: Less to Fear Than Originally Thought?Journal of clinical and experimental hepatologyArticle
- Outcomes of COVID-19 in Patients with Cirrhosis or Liver Transplantation.Journal of clinical and experimental hepatologyReview
- Impact of the COVID-19 Pandemic on Patients with End-Stage Liver Disease: One Virus-A Plethora of Consequences.Journal of clinical and experimental hepatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adverse clinical outcomes related to SARS-CoV-2 infection among liver transplant (LTx) recipients remain undefined. We performed a meta-analysis to determine the pooled prevalence of outcomes among hospitalized LTx recipients with COVID-19. A database search of literature published between December 1, 2019, and November 20, 2020, was performed per PRISMA guidelines. Twelve studies comprising 517 hospitalized LTx recipients with COVID-19 were analyzed. Common presenting symptoms were fever (71%), cough (62%), dyspnea (48%), and diarrhea (28%). Approximately 77% (95% CI, 61%-93%) of LTx recipients had a history of liver cirrhosis. The most prevalent comorbidities were hypertension (55%), diabetes (45%), and cardiac disease (21%). In-hospital mortality was 20% (95% CI, 13%-28%) and rose to 41% (95% CI, 19%-63%) (P < 0.00) with ICU admission. Additional subgroup analysis demonstrated a higher mortality risk in the elderly (>60-65 years) (OR 4.26; 95% CI, 2.14-8.49). There was no correlation in respect to sex or time since transplant. In summary, LTx recipients with COVID-19 had a high prevalence of dyspnea and gastrointestinal symptoms. In-hospital mortality was comparable to non-transplant populations with similar comorbidities but appeared to be less than what is reported elsewhere for cirrhotic patients (26%-40%). Importantly, the observed high case fatality in the elderly could be due to age-associated comorbidities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.